News Briefs AIDS Drug in Halted Trial Is Less Effective Taken AloneMarch 13, 2003 A note from TheBody.com: The field of medicine is constantly evolving. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! The US National Institutes of Health halted the trial of
GlaxoSmithKline's AIDS drug Trizivir after it proved less
effective than when used in combination with another AIDS drug,
the company said. A Glaxo spokesperson said the NIH's AIDS
clinical trial conducted three studies in parallel, one of which
tested patients taking just Trizivir. In two further studies,
some patients took a combination of the Bristol-Myers Squibb Co.
drug Sustiva with Trizivir, while others took a combination of
Glaxo's drug Combivir with Sustiva. NIH decided to stop the
Trizivir-only trial because only 74 percent of patients had a
viral load of less than 200 after 48 weeks. In the other two
trials, 89 percent of patients achieved a viral load of less than
200.
Adapted from:Wall Street Journal 03.13.03 A note from TheBody.com: The field of medicine is constantly evolving. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
|